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Abstract
Patients with Chronic Chagas’ Heart Disease possess high levels of antibodies against the carboxyl-terminal end of the
ribosomal P2ß protein of Trypanosoma cruzi (TcP2ß). These antibodies, as well as the murine monoclonal antibody (mAb)
17.2, recognize the last 13 amino acids of TcP2ß (called the R13 epitope: EEEDDDMGFGLFD) and are able to cross-react with,
and stimulate, the ß1 adrenergic receptor (ß1-AR). Indeed, the mAb 17.2 was able to specifically detect human b1-AR, stably
transfected into HEK cells, by flow cytometry and to induce repolarisation abnormalities and first degree atrioventricular
conduction block after passive transfer to naı ¨ve mice. To study the structural basis of this cross-reactivity, we determined
the crystal structure of the Fab region of the mAb 17.2 alone at 2.31 A ˚ resolution and in complex with the R13 peptide at
1.89 A ˚ resolution. We identified as key contact residues on R13 peptide Glu3, Asp6 and Phe9 as was previously shown by
alanine scanning. Additionally, we generated a model of human b1-AR to elucidate the interaction with anti-R13 antibodies.
These data provide an understanding of the molecular basis of cross-reactive antibodies induced by chronic infection with
Trypanosoma cruzi.
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Introduction
Trypanosoma cruzi, the etiological agent of Chagas’ disease, affects
approximately 10–12 million people from different endemic
regions in Latin America [1], killing more than 15,000 each year
[2,3]. It is also carried by hundreds of thousands of people in
Europe (especially Spain and Portugal), the United States,
Canada, Japan and Australia, mostly by Latin American
immigrants. Accordingly, infection control of blood banks has
been recently implemented outside endemic regions [4]. Chagas’
disease shows a variable clinical course, which ranges from an
acute phase, with parasitemia and asymptomatic features, to
serious chronic symptomatic stages characterized by low or no
parasitemia, positive serology and involving clinical cardiac,
gastrointestinal or neurological disorders [3,5]. The cardiac form,
referred as chronic Chagas’ heart disease (cChHD), is not only the
most frequent and severe consequence of the chronic infection by
T. cruzi, but is also the main cause of cardiomyopathy in South and
Central America [6]. Among other clinical features, cChHD is an
arrhythmogenic cardiomyopathy with high prevalence of right
bundle branch block, left anterior hemi block, sinus node
dysfunction and complex supraventricular arrhythmias [7,8];
mega disorders of colon or esophagus and neurological disorders
are less frequent (around 5% of the infected people) [9,10]. To
date, the mechanisms of the pathophysiology of Chagas’ disease
are not completely understood and two main hypotheses have
been proposed: the first is based on the essential role of the parasite
in tissular damage while the second argues for an auto reactive
process resulting from an impaired immune response associated
with molecular mimicry [11,12,13]. Different experimental
approaches have shown that both mechanisms may be involved
in the chagasic pathology because of the persistence of the parasite
in chronic phase [14] and of the presence of parasite antigens
carrying epitopes common to host molecules [15].
In 1989, Levin et al. selected and cloned the first parasite
molecule, called JL5, presenting a molecular mimicry of a human
molecule, using serum from a chronically infected person with
cChHD [16,17]. The fine epitope recognized by patients with
cChHD was located at the C-terminal end of the T. cruzi
ribosomal P2b protein (TcP2b) and was named R13
www.plosntds.org 1 November 2011 | Volume 5 | Issue 11 | e1375(EEEDDDMGFGLFD) [15,18,19,20]. This highly antigenic
acidic epitope bears similarity to an acidic motif (AESDEA) on
the second extracellular loop of cardiac b1-adrenergic receptor
(b1-AR) [21,22]. In addition, a significant correlation between the
high level of anti-R13 antibodies (Abs) and ventricular arrhythmias
was observed [23], consistent with the hypothesis that R13-specific
anti-TcP2b Abs are able to cross-react with and stimulate the b1-
AR [19,20,21,22,23,24,25]. Alanine-mutation scanning experi-
ments on the R13 epitope using different immuno-purified anti-
R13 Abs illustrated the complexity of the anti-R13 humoral
response since each of the eight anti-R13 Ab preparations
presented a unique epitope recognition pattern [23]. Despite this
extreme heterogeneity, it was possible to determine a common
reactivity profile where Glu3, and to a lesser extent, Asp6 and
Phe9 were essential [23]. Indeed, the C-terminal end of the human
ribosomal P proteins has one single amino acid change in the third
residue (Glu3Ser), a change that diminished the affinity of mAb
17.2 for the corresponding mammalian peptide by about two
orders of magnitude [22].
Mice immunized with different recombinant TcP2b proteins
(GST or His fusion proteins) and different adjuvants (CFA or
ALU) induced a diverse response along the protein sequence.
Strikingly, Abs from infected animals recognized only the C-
terminal region of the protein (R13 epitope). These different
antiserum showed that only Abs specific for the C-terminus were
able to increase the beating frequency of cardiomyocytes from
neonatal rats in vitro by selective stimulation of the b1-AR [24].
These immunization data led to protocols for the production of a
monoclonal antibody directed against the R13 epitope, the mAb
17.2. This mAb was demonstrated to i) recognize a linear epitope
of the C-terminal end of TcP2b protein (R13), ii) react with
peptides derived from the second extracellular loop of the human
b1-AR, iii) induce a dose-dependent increase on the beating
frequency of cardiomyocytes in culture that is abolished by
bisoprolol, a specific b1-AR antagonist [22], and iv) provoke
apoptosis in murine cardiac cell lines, HL-1 [26].
In the present work, we report the three-dimensional structure
of the Fab fragment of mAb 17.2 determined by X-ray
crystallography, alone and in complex with its cognate peptide
epitope, providing a description of structural changes that occur
upon binding the antigen. The mAb 17.2 was shown by flow
cytometry to specifically detect HEK cells transfected with the
human b1-AR. In addition, passive transfer to naı ¨ve mice induced
some of the classical symptoms of the Chagasic cardiomyopathy,
such as repolarisation abnormalities and first degree atrioventric-
ular (AV) conduction block. Finally, we discuss the relationship
between epitope mimicry and bystander activity of anti-R13 Abs
on the b1-AR using our crystal structure of the Fab 17.2 in
complex with a model of the human b1-AR constructed from the
turkey b1-AR structure that was recently determined [27].
Materials and Methods
1. Ethics statement
The research was conducted in accordance with the European
Community guidelines for use of experimental animals. The
IBMC animal house facilities are approved by French veterinary
service (#E67-482-2). No surgery has been done on animals. Mice
were euthanized according the European Community guidelines.
2. Preparation and purification of mAb 17.2
The mAb 17.2 (isotype IgG1, k) was obtained by immunizing
BALB/c mice with recombinant TcP2b [22]. The mAb was
purified from ascitic fluid by precipitation with 40% ammonium
sulphate at pH 7.4, followed by ion-exchange chromatography on
a DEAE-Sephacel (Pharmacia, Sweden) column equilibrated in
17.5 mM NaCl at pH 8.0. The elution was done with 40 mM
NaCl at pH 8.0. The sample was then dialyzed against 0.1 M
potassium phosphate at pH 7.2.
After addition of 5 mM b-mercaptoethanol and 2.5 mM
EDTA, the IgG was treated with papain at an enzyme:substrate
ratio of 1:100 at 37uC for 2 h. The reaction was stopped by
addition of iodacetamide (1 mg/ml) before dialysis against 10 mM
sodium phosphate at pH 8.0. The Fab was then added to a
DEAE-Sephacel (Pharmacia, Sweden) column equilibrated with
the same buffer. Fab 17.2 was eluted with phosphate buffer and
then concentrated on a Centricon 10.
3. Synthetic peptide
R13 peptide (EEEDDDMGFGLFD, representing the C-
terminal region of TcP2b) was synthesized by the solid-phase
method of Merrifield [28], with a semi-automatic multi-synthe-
sizer NPS 4000 (Neosystem, France).
4. Crystallization of the complex Fab 17.2
Crystals of apo Fab 17.2 and its complex with R13 were grown
by vapour diffusion using the hanging drop technique. One
volume of Fab 17.2 at 10 mg/ml was mixed with one volume of a
solution consisting of 18% (w/v) PEG 8000, 0.1 M sodium
cacodylate at pH 6.7, 0.2 M calcium acetate, 12.5 mM Tris-HCl
pH 7.5 and 25 mM NaCl. The drop, with a final protein
concentration of 4.2 mg/ml, was sealed over a reservoir
containing 1 ml of mother liquor. Crystallization of the Fab
17.2/R13 peptide was performed under the same conditions as
above with Fab and peptide concentrations of 15 mg/ml and
10 mg/ml, respectively, giving an Ab/antigen molar ratio ,1/20.
5. Crystallographic data and structure solution
Diffraction data were collected on the beam lines ID14-1 (Fab
17.2/R13 complex) and BM30A (apo Fab 17.2) at the European
Synchrotron Radiation Facility, Grenoble, France. The two
crystal forms belong to space group P21 with very similar unit
cell parameters. Diffraction data were integrated and scaled using
the programs HKL and SCALEPACK [29]. The structure was
solved by molecular replacement with the program AMoRe [30],
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Trypanosoma cruzi is a protozoan parasite responsible for
Chagas disease. Chronic Chagas’ heart disease (cChHD) is
not only the most frequent and severe consequence of the
chronic infection by T. cruzi, but is also the main cause of
cardiomyopathy in South and Central America. Patients
with cChHD possess high levels of antibodies against the
carboxyl-terminal tail of the ribosomal P proteins of T. cruzi
(called the R13 epitope). These antibodies, as well as the
murine monoclonal antibody (mAb) 17.2, are able to cross-
react with, and stimulate, the ß1 adrenergic receptor (ß1-
AR). Indeed, the mAb 17.2 was able to specifically detect
human b1-AR and induce some of the classical cardiac
symptoms after passive transfer to mice. To study the
structural basis of this cross-reactivity, we determined the
crystal structure of the Fab region of the mAb 17.2 alone
and in complex with R13. Additionally, we generated a
model of human b1-AR to elucidate the interaction with
anti-R13 antibodies in order to understand the molecular
basis of cross-reactive antibodies induced by chronic
infection with T. cruzi.
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entry 2igf as search models. Two independent Fab molecules,
expected from the unit cell volume, were readily located and the
structure was refined using the program autoBUSTER (Global
Phasing Ltd.). Manual adjustments between refinement runs and
building of the R13 peptide in the complex were performed with
the program COOT [31]. Crystallographic parameters, diffrac-
tion data statistics and structure refinement results are summarized
in Table 1.
6. b1-AR competition binding experiments
HEK cells and HEK cells transfected with b1-AR (HEK-b1)
were cultured in DMEM (GIBCO, Invitrogen, USA) with 10%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine, using 200 mg/ml hygromycin B (Sigma, USA) for
transfected cell maintenance [25].
HEK and HEK-b1 cells were seeded in FACS tubes at 8610
5
cell/ml and incubated with mAb 40.14 or 17.2 (500 nM) or with
mAb 17.2 (500 nM) pre-incubated for 2 h at 37uC with 10 mM
R13 peptide in supplemented DMEM. After 1 h at room
temperature, cells were stained with Cy3-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch, USA) and propidium
iodide (PI) to exclude the dead cell population. Cells were detected
using a BD FACSARIA flow cytometer (BD Biosciences) and
results were analysed with WinMdi 2.9 software (Copyright 1993–
2000 Joseph Trotter). Values are expressed as means 6 S.D.
(n=3) and statistical comparisons were performed using One-way
and Two-way ANOVA with Bonferroni’s Multiple Comparison
post test using GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.
com. P,0.05 was considered statistically significant.
7. Electrocardiogram recordings
Three female BALB/c mice, 20 g each, were anesthetized using
intraperitoneal Tribromoethanol 150 mg/Kg. The mAb 17.2 was
injected intravenously at 200 nM in 200 ml of saline solution (0.9%
NaCl). Electrocardiogram (ECG) recordings were performed
during 30 min after injection. ECGs were obtained with the six
standard leads (I, II, III, AVR, AVL, AVF) at 50 mm/s of paper
speed and at 20 mm/mV amplitude using a Fukuda-Denshi Fx-
2111 electrocardiograph (Tokyo, Japan) [32]. Electrocardiograph-
ic analysis included measurements of heart rate, P wave duration
and amplitude, QRS complex duration and amplitude, P-R
interval duration and a search for disturbances of rhythm,
conduction, and repolarisation.
8. Molecular modelling
All procedures were performed with Discovery Studio 2.5
software from Accelrys (San Diego, CA, USA). The crystal
structure of the turkey b1-AR (PDB 2VT4) was used as template to
build a model of the human b1-AR. We mutated all residues to the
human sequence and optimized the conformation of both the
mutated residues and any surrounding residues that lay within a
cut-off radius of 2 A ˚. Five models thus obtained were scored by the
Discrete Optimized Protein Energy (DOPE). We continued
analysis using the lowest energy model (DOPE=239358.55 k-
cal/mol), which was superimposed onto a membrane model. The
R13 epitope structure was aligned with the second extracellular
loop of the humanized b1-AR model to allow positioning of the
Ab on the putative cross-reactive epitope. Once the Ab was
positioned, a fixed atom constraint was applied to the whole b1-
AR with the exception of the extracellular regions and a harmonic
restraint was applied to the frame work regions of the Ab. Finally,
the complex was subjected to an initial minimization step (max
500), RMS gradient 0.1 Kcal/mol by conjugated gradient;
followed by a second minimization step (max 500), RMS gradient
0.0001 Kcal/mol by conjugated gradient. The structure was then
submitted to a dynamic simulation including heating (2000 steps),
equilibration (1000 steps) and production (1000 steps) at 300 uK
with a time step of 0.001 ps under a distance-dependent, dielectric
constant, implicit solvent model. A negative intermolecular energy
of 2430 kcal/mol was obtained for the complex under these
conditions. All images were generated using PyMOL Molecular
Graphics System, Version 1.0, Schro ¨dinger, LLC.
Results
Structure of apo Fab 17.2 and its complex with R13
We determined the crystal structure of the Fab region of the
mouse monoclonal antibody 17.2, in the apo form and in complex
with the peptide R13 (EEEDDDMGFGLFD), corresponding to
the C-terminal epitope of TcP2b. The asymmetric unit of both
crystal structures contains two independent apo Fab molecules or
Fab-R13 complexes (referred as molecule 1 and 2). The N- and C-
termini of R13 show considerable mobility and only the first
eleven amino acid residues (EEEDDDMGFGL) in both complexes
could be traced in the electron density maps. The two independent
Fab molecules of each crystal form show small differences in
quaternary structure, as revealed by the difference in elbow angle
(angle subtended by the pseudo two-fold axes of the variable and
constant dimers). The Fab 17.2 elbow angles are 152/144u and
150/146u for the apo and R13 complex, respectively (molecule1/
molecule2), and lie within the range of previously reported values
[33]. These reflect the different lattice environments of the two
independent molecules in the asymmetric unit since the respective
Table 1. Crystallographic data and refinement statistics.
Fab 17.2 - R13
(EEEDDDMGFGLFD) Fab 17.2 apo
Space group P21 P21
Cell parameters a
b
c
(A ˚)
83.00
68.21
92.11
82.07
65.68
91.37
b (u) 98.4 98.2
Resolution (A ˚) 30.0–1.89 1.94–1.89 30.0–2.29 2.34–2.29
Total reflections 282283 144,460 2210
Unique reflections 73,918 3090 41,572 1458
Rmerge 0.077 0.405 0.049 0.170
Completeness (%) 92.0 57.9 94.6 50.7
d 14.6 2.7 22.9 4.2
Redundancy 3.82 3.82 3.47 3.47
B Wilson (A ˚2) 28.8 28.8
Refinement
Resolution (A ˚) 20.0–1.89 1.94–1.89 20.0–2.31 2.37–2.31
Rfactor 0.1795 0.2107 0.1724 0.2013
Rfree 0.2178 0.2459 0.2355 0.3122
rms bonds (A ˚) 0.010 0.010
rms angle (u) 1.15 1.25
doi:10.1371/journal.pntd.0001375.t001
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forms, which are closely isomorphous.
No significant structural differences were observed between
individual variable domains. A pair-wise superposition of all VL
domains from the apo and R13 complex Fab molecules gives a
mean r.m.s. difference in Ca position of 0.28 A ˚ (range 0.23–
0.34 A ˚). Similarly, the superimposed VH domains give a mean
r.m.s. difference in Ca positions of 0.28 A ˚ (range 0.23–0.33 A ˚).
For both VH and VL, the largest differences occur between the
R13 complex and apo forms, but these are small, showing that
the polypeptide conformation was largely conserved upon
binding the antigen. The most notable structural change to
occur upon binding R13 is a small relative rotation between the
VL and VH domains, leading to an opening out at the antigen-
binding site when the antigen is bound, with a 4.2u rotation from
the apo to R13 complex state for molecule 1 and 4.6u for
molecule 2. The distance between the tips of CDR-L1 and CDR-
H2 is correspondingly shifted from 15.7 A ˚ and 16.8 A ˚ in the apo
structure to 18.9 A ˚ and 18.2 A ˚ in the R13 complex in molecules
1 and 2, respectively (Figure 1). Interestingly, side chain
conformations at the antigen binding site are entirely conserved
upon binding the antigen (Figure 2A). In addition, there are six
water molecules within the Fab 17.2 antigen combining site in the
apo structure that are displaced by the peptide in the Fab 17.2
R13 complex (Figure 2B). Two of the water molecules in the
apo structure are replaced by the side chains of Glu3 and Asp6,
supporting the pivotal role of these residues in the antibody-
antigen interaction. The remaining four waters are displaced by
the main chain of the peptide, residues Met7 to Gly10
(Figure 2C). The complex structure also reveals two water-
mediated interactions between the peptide and the CDR-H1
(Thr31 and Asn32) engaging both side and main chain atoms of a
single epitope residue, Asp4.
The two bound R13 peptides from the complexes in the
asymmetric unit are similar in structure, superimposing with an
r.m.s. difference in Ca positions of 0.78 A ˚ (1.06 A ˚ for all main
chain atoms). The peptide structures diverge most at the N- and
C-termini, where contacts with the antibody are sparse, but are
very similar in the central region of the peptide between residues
Asp3 and Gly10 (Figure 2D). Antibody-peptide interactions are
similar in the two independent Fab 17.2-R13 complexes and
include 13 hydrogen bonds, four with VL and nine with VH, as
well as a salt bridge between VH Arg52 and R13 Glu3 (Table 2).
In addition, an aromatic stacking interaction occurs between VL
Tyr101 and R13 Phe9. These results highlight the importance of
some key contact residues on the epitope, such as Glu3, Asp6 and
Phe9 (Figure 2E).
Functional activity of the mAb 17.2
The cross-reaction of anti-R13 Abs with b1-AR has been
extensively reported [22,23,24,34]. Indeed, the mAb 17.2, first
described by Mahler et al (2001) [22], induced a dose-dependent
increase on the beating frequency on neonatal rat cardiomyocytes
culture that was abolished by bisoprolol, a specific b1-AR
Figure 1. Structure of the Fab 17.2. A. Apo Fab 17.2 structure (molecule 1). Heavy chain CDRs are coloured in red and light chain CDRs in blue. B.
Superposition of molecules 1, VH-VL region of the two crystals asymmetric units. C. Superposition of molecules 2, VH-VL region of the two crystals
asymmetric units. Apo Fab 17.2 (grey), Fab 17.2-R13 molecule 1 (green) and molecule 2 (magenta).
doi:10.1371/journal.pntd.0001375.g001
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specifically recognized human b1-AR presented in a stable HEK-
b1 cell line (Figure 3A and B). This cell line possesses a high
receptor expression (800–1300 fmol/mg of total protein), as has
been previously reported [35]. The mAb 40.14, which recognizes
an internal epitope on TcP2b, gave no signal, indicating the
specificity of mAb 17.2-b1-AR interaction (Figure 3B). In
addition, this interaction was inhibited by pre-incubation of the
mAb 17.2 with R13 peptide (Figure 3B inset). Furthermore,
passive transfer of mAb 17.2 to naı ¨ve mice induced an increase in
the beating rate from 240 bpm to 300 bpm after 30 minutes
(Figure 3C). Repolarisation abnormalities (a) and first degree AV
conduction block (b) were recorded at 15 and 30 minutes post-
injection.
Modelling the interaction with the human b1-AR
In view of the functional activity of the Ab on b1-AR, we
generated a model of the interaction of the Fab 17.2 with the
human receptor from the crystal structure of the turkey
homologue. Briefly, we generated a model of the human b1-AR
as described under material and methods. The structure of TcP2b
epitope, R13, was aligned to the humanized second extracellular
Figure 2. Structure of the Fab17.2 – R13 complex. A. Superposition of the apo Fab 17.2 and R13 complex structures (grey and green
respectively). VH and VL contact residues are indicated. B. Main water molecules present on the antigen binding site of Fab 17.2 apo. C. Superposition
of water molecules present in the apo Fab 17.2 that are replaced by the peptide in the Fab 17.2 R13 complex. D. Superposition of R13 peptides from
molecules 1 (green) and 2 (magenta). E. Structure of the Fab 17.2-R13 complex (molecule 1). All hydrogen bonds between mAb 17.2 and peptide R13
are illustrated as dotted yellow lines. The p-stacking interaction between VL Tyr101 and the epitope Phe9 is also indicated. Heavy chain CDRs are
coloured in red and light chain CDRs in blue the peptide is coloured in light green.
doi:10.1371/journal.pntd.0001375.g002
Table 2. Polar contacts between Fab 17.2 and R13 peptide.
Fab CHAIN CDR Atom [MC/SC] Ag
Asn39 L 1 Nd2 [SC] … O [MC] Gly8
Arg51 L 2 Ng2 [SC] … O [MC] Asp6
Arg51 L 2 Ng1 [SC] … O [MC] Asp6
Gly96 L 3 O [MC] … N [MC] Gly10
Thr31 H 1 O [MC] … N [MC] Asp4
Asn32 H 1 Nd2 [SC] … Od1 [SC] Asp4
Arg52 H 2 Ng1 [SC] … Oe2 [SC] Glu3
Ser53 H 2 N [MC] … Oe1 [SC] Glu3
Ser53 H 2 Oc [SC] … Oe1 [SC] Glu3
Asn56 H 2 Nd2 [SC] … Oe1 [SC] Glu3
Thr102 H 3 N [MC] … Od2 [SC] Asp6
Thr102 H 3 Oc1 [MC] … Od1 [SC] Asp6
Thr103 H 3 N [MC] … Od2 [SC] Asp6
Thr103 H 3 Oc1 [SC] … Od2 [SC] Asp6
MC: Main Chain; SC: Side Chain.
doi:10.1371/journal.pntd.0001375.t002
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putative binding site (Figure 4A) and the complex was subjected
to a two minimization steps followed by heating, equilibration and
production protocols under a distance-dependent, dielectric-
implicit solvent model (Figure 4B). The interaction energy of
the complex Ab-b1-AR was estimated at 2430 kcal/mol. Polar
contacts found in the model are summarized in Table 3. Some of
Ab residues identified in the interaction with the humanized 2ECL
peptide were key residues in the interaction with the T. cruzi
epitope, such as Thr31, Arg52 and Asn56 of the heavy chain. In
addition, the acidic residues present on the humanized b1-AR
model (Asp187, Glu188, Asp195 and Asp200) established many
hydrogen bonds with different residues of the Fab (Figure 4C).
Remarkably, while the light chain established just a few contact
points with the T. cruzi epitope, it established many hydrogen
bonds with b1-AR, as can be seen in Figure 4 and Table 3,
suggesting an important role in stabilizing the interaction with the
receptor.
Figure 3. Functional activity of the mAb 17.2. A. Representative histogram showing the HEK and HEK-b1 cells labelled with mAb 17.2 followed
by a Cy3-conjugated goat anti-mouse IgG. B. Results are expressed as means 6 SD (n=3). Inset: Binding of mAb 17.2 to HEK-b1 cells in the presence
of R13 peptide. ** p,0.01; *** p,0.001. C. Passive transfer of mAb 17.2 to naı ¨ve mice. Repolarisation abnormalities (a) and first degree AV conduction
block (b) are indicated by arrows. bpm: beats per minute.
doi:10.1371/journal.pntd.0001375.g003
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Alanine-mutation scanning analysis on the R13 epitope showed
the importance of Glu3, Asp5, Asp6, Gly8 and Phe9 for mAb 17.2
recognition [22]. Crystal structure confirmed the interaction of
Glu3, Asp6, Gly8 and Phe9 with the antibody and exposed a polar
contact between Asp5 and Met7. This interaction may contribute
to stabilize the conformation of the peptide that was shown to
behave as random coil in solution [36].
Despite the sequence similarity between the epitope sequence
(EEEDDDMGFGL) of TcP2b and the acidic region on the
human second extracellular loop (AESDEA) of b1-AR, crystallo-
graphic data and modelling showed that this minimal region is
involved but not sufficient for an effective interaction. The
interaction energy between the Fab and the whole receptor was
estimated at 2430 kcal/mol. However, the interaction energy of
the Ab with only the 2ECL was 2283 kcal/mol, suggesting that
other regions on the receptor contribute to stabilize the interaction
within the complex. These data could also explain the low affinity
of mAb 17.2, or single chain derived recombinant antibodies, with
the b1-AR 2ECL peptide H26R measured by surface plasmon
resonance [22,25]. It is possible that electrostatic forces guide the
first contacts between an electropositive antigen-binding pocket
and the electronegative region of the 2ECL, with the heavy and
light chains establishing additional contacts with the receptor.
Comparison of the buried surfaces in both crystallized complex
and the model (Table 4) shows a larger surface for the complex
with the b1-AR, supporting this hypothesis. However, the shape
complementarities for the model-Fab complex were smaller in
comparison to R13 complex (Table 4), suggesting a reduced
affinity for the b1-AR. Together, these data support the idea of a
bystander activity of mAb 17.2 on the cardiac receptor rather than
classical epitope mimicry of acidic residues.
Recently, the crystal structure of turkey b1-AR in complex with
different agonists and antagonists was published [37]. In this work,
the authors showed the presence of structural differences between
the 2ECL of the b1-AR bound to the agonist dobutamine (PDB
2Y01) and to the antagonist cyanopindolol (PDB2VT4). A 1 A ˚
contraction of the ligand-binding pocket between helices H5 and
H7 was observed in the agonist complex relative to the antagonist
complex. The contraction of the catecholamine-binding pocket
induced a conformational change in the 2ECL [37]. In addition,
we previously reported the construction of two single chain
recombinant antibodies (scFv) derived from the mAb 17.2, named
scFv C5 and B7 [25]. Both scFv were able to recognize T. cruzi
ribosomal P proteins and b1-AR in Western blot, ELISA, surface
plasmon resonance and immunofluorescence. In functional assays,
however, the monomeric scFv B7 behaved as a b1-AR antagonist,
while the dimeric scFv C5 acted as a b1-AR agonist. The
interaction of the Fab fragment with the b1-AR should thus
correspond to an antagonist conformation. A dimeric interaction
of the Ab with the receptor would, however, be constrained by the
distance of the two antigen-binding sites on the dimeric Ab. Since
b1-AR forms a family of dimeric membrane proteins, we
suggested that the interaction constraints between the two dimers
require a small rearrangement of the receptor dimer, decreasing
the pharmacophore pocket, as has been described for partial
agonists [37]. This could explain the experimental observation
that monomeric fragments of Abs against the second extracellular
loops of b1-AR act as inverse agonists while the bivalent fragments
or dimeric antibodies behave as partial agonists [25,38,39,40].
Figure 4. Model of the interaction of Fab 17.2 with the human b1-AR. A. Superposition of the second extracellular loop (2ECL) of the human
b1-AR model (violet) and the region 2–5 of the epitope (light green). B. Complex of the Fab 17.2 (light green) with the human b1-AR (violet) inserted
in a membrane model (grey). C. Zoom of the paratope region of 17.2 interacting with the second extracellular loop. The main contact points are
illustrated as dotted yellow lines. Heavy chain CDRs are coloured in red and light chain CDRs in blue.
doi:10.1371/journal.pntd.0001375.g004
Table 3. Polar contacts in the model between 17.2 and b1-
AR.
mAb CHAIN CDR Atom [MC/SC] b-1AR
Gln27 L 1 Oe1 [SC] … Hg22[SC] Arg323
Ser28 L 1 Oc[SC] … Hg11[SC] Arg323
Asp31 L 1 Od2 [SC] … Hv[MC] Arg323
Ser32 L 1 Oc[SC] … Hv[MC] Val326
Lys35 L 1 Hf1 [SC] … Od1 [SC] Asp200
Lys35 L 1 Hf1 [SC] … Od2 [SC] Asp200
Lys35 L 1 Hf2 [SC] … Od2 [SC] Asp200
Lys58 L 2 Hf1 [SC] … O [MC] Lys197
Lys58 L 2 Hf2 [SC] … Od1 [SC] Asp195
Lys58 L 2 Hf3 [SC] … Od1 [SC] Asp195
Lys58 L 2 Hf3 [SC] … Od2 [SC] Asp195
His98 L 3 Hd1 [SC] … O [MC] Asp322
Thr31 H 1 Hc1 [SC] … Od2 [SC] Asp187
Asn32 H 1 Hd22[SC] … Od1 [SC] Asp187
Arg50 H 2 Hg22 [SC] … Oe1 [SC] Glu188
Arg52 H 2 Hg12 [SC] … Oe2 [SC] Glu188
Arg52 H 2 Hg22 [SC] … Oe2 [SC] Glu188
Asn56 H 2 Od1 [SC] … Hg11 [SC] Arg317
Asn57 H 2 Od1 [SC] … Hg11 [SC] Arg205
Asn57 H 2 O [MC] … Hg12 [SC] Arg205
Ser59 H 2 Oc[SC] … Hg12 [SC] Arg205
Ser59 H 2 Oc[SC] … Hg22 [SC] Arg205
Tyr61 H 2 Hg [SC] … O [MC] Phe315
Arg100 H 3 Hg21 [SC] … Od1 [SC] Asp187
MC: Main Chain; SC: Side Chain.
doi:10.1371/journal.pntd.0001375.t003
Table 4. Buried surface upon complex formation, with shape
complementarities (Sc) [50] and number of contacts observed
between the mAb 17.2 and the R13 peptide in the crystal
structure
1 and the model
2.
Fab17.2 – R13
1 Fab17.2 - b1AR
2
Surface (A ˚2)A b ( V L/VH) 648 (252.7/395.3) 1414.9 (868.3/546.6)
Ag 845 2972.1
Total 1493 4387
Sc 0.77 0.614
Nu contacts Polar 14 46
Total 32 96
doi:10.1371/journal.pntd.0001375.t004
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pathogenesis of cChHD is still controversial. Chronic Chagas’
patients develop Abs against G protein-coupled receptors such as
b1-AR, b2-AR and M2-AChR and there are different profiles of
these Abs accordingly with the clinical outcome [23,41,42]. In the
case of cChHD, there is a prevalence of b1-AR and M2-AChR
Abs [43]. Interestingly these Abs can be detected before the
clinical manifestations, supporting the hypothesis of Abs as
pathogenic driver for clinical manifestations such as cardiomyop-
athy or megacolon [43]. It is well documented that chronic
adrenergic stimulation mediated by antibodies may have a cardio-
toxic effect resembling that caused by catecholamine, which
induce cardiac changes similar to those observed in Chagas’
disease; namely induction of micro focal lesions associated with a
mononuclear cell infiltrate with increased involvement of the left
ventricle, and particularly the left ventricular apex
[44,45,46,47,48]. Moreover, IgGs from cChHD patients as well
as the monoclonal antibody 17.2 were able to provoke apoptosis
on HL-1 cardiac cell line, effect that was diminished by either R13
peptide or propranolol [26], reinforcing the pathogenic role of
anti-R13 Abs acting on the b1-AR.
Our data provide a molecular basis for the understanding of the
ß1-AR bystander activation by anti-R13 Abs. Furthermore, as
severe cases of chronic Chagas’ Heart Disease are related to high
levels of Abs directed against the R13 epitope [8,17,18,19,20,
23,49], and immuno-purified anti-R13 Abs from some of these
patients showed in common that R13 residues Glu3, Asp6 and
Phe9 were essential for recognition [23] (as was shown for mAb
17.2), we suggest that high blood concentrations of these
antibodies may exert a systemic effect by inducing functional
changes in cell types and tissues expressing this receptor, thereby
increasing liability to chronic pathology from T. cruzi infection.
Acknowledgments
We thank Dr. Sylviane Muller and Prof. Sylvie Fournel (UPR 9021
Strasbourg, France) for helpful collaboration in the publication of this
article; Maximiliano Juri-Ayub and Josiane Gregoire for production and
purification of mAb 17.2 and A. Benatar for his collaboration with FACS
experiments. HEK-b1 cells were kindly provided by Dr. Federico Mayor
Jr. (Universidad Auto ´noma de Madrid, Spain). We thank the staff of the
European Synchrotron Radiation Facility, Grenoble, France, for providing
facilities for diffraction measurements and for assistance.
In memory of Dr. Mariano J. Levin (1951–2010), Director of the Laboratory of
Molecular Biology of Chagas’ disease, INGEBI-CONICET, Buenos Aires, Argentina,
from 1985 to 2010.
Author Information
Coordinates have been submitted to the PDB database under accession
codes 3SGD and 3SGE for Fab 17.2 apo and Fab 17.2-R13 complex
respectively.
Author Contributions
Conceived and designed the experiments: GAB MJL MH CRS. Performed
the experiments: JCP GB GAB KAG MH CRS. Analyzed the data: JCP
GAB KAG JH CRS. Contributed reagents/materials/analysis tools: KAG
MJL MH GAB CRS. Wrote the paper: JCP GAB MH CRS.
References
1. Moncayo A, Silveira AC (2009) Current epidemiological trends for Chagas
disease in Latin America and future challenges in epidemiology, surveillance and
health policy. Mem Inst Oswaldo Cruz 104 Suppl 1: 17–30.
2. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control.
Trends Parasitol 22: 583–588.
3. (2002) Control of Chagas disease. World Health Organ Tech Rep Ser 905: i–vi,
1–109, back cover.
4. Hontebeyrie M, Brenie `re SF, Aznar C (2010) Others forms of transmission in
American Trypanosomiasis Chagas disease, One hundred years of research.
edited by J Telleria and M Tibayrenc, Elsevier. pp 583–597.
5. Rassi A, Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet 375: 1388–1402.
6. Rassi A, Jr., Rassi A, Little WC (2000) Chagas’ heart disease. Clin Cardiol 23:
883–889.
7. Elizari MV, Chiale PA (1993) Cardiac arrhythmias in Chagas’ heart disease.
J Cardiovasc Electrophysiol 4: 596–608.
8. Chiale PA, Ferrari I (2001) Autoantibodies in Chagas’ cardiomyopathy and
arrhythmias. Autoimmunity 34: 205–210.
9. Koberle F (1968) Chagas’ disease and Chagas’ syndromes: the pathology of
American trypanosomiasis. Adv Parasitol 6: 63–116.
10. Palmieri JR, LaChance MA, Conner DH (1984) Parasitic infection of the
peripheral nervoussystem.In: PJ Dyck, PK Thjomas, EH Lambert, R Bunge,
eds. Peripheral Neuropathy 2: 1988–2009.
11. Kierszenbaum F (1999) Chagas’ disease and the autoimmunity hypothesis. Clin
Microbiol Rev 12: 210–223.
12. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV (2007) Pathogenesis of
chronic Chagas heart disease. Circulation 115: 1109–1123.
13. Hontebeyrie M, Truyens C, Brenie `re SF (2010) Pathological consequences of
host response to parasite in American Trypanosomiasis Chagas disease, One
hundred years of reresearch. edited by J Telleria and M Tibayrenc, Elsevier. pp
669–690.
14. Brandariz S, Schijman A, Vigliano C, Arteman P, Viotti R, et al. (1995)
Detection of parasite DNA in Chagas’ heart disease. Lancet 346: 1370–1371.
15. Aznar C, Lopez-Bergami P, Brandariz S, Mariette C, Liegeard P, et al. (1995)
Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection.
FEMS Immunol Med Microbiol 12: 231–238.
16. Levin MJ, Mesri E, Benarous R, Levitus G, Schijman A, et al. (1989)
Identification of major Trypanosoma cruzi antigenic determinants in chronic
Chagas’ heart disease. Am J Trop Med Hyg 41: 530–538.
17. Mesri EA, Levitus G, Hontebeyrie-Joskowicz M, Dighiero G, Van
Regenmortel MH, et al. (1990) Major Trypanosoma cruzi antigenic
determinant in Chagas’ heart disease shares homology with the systemic lupus
erythematosus ribosomal P protein epitope. J Clin Microbiol 28: 1219–1224.
18. Levitus G, Hontebeyrie-Joskowicz M, Van Regenmortel MH, Levin MJ (1991)
Humoral autoimmune response to ribosomal P proteins in chronic Chagas heart
disease. Clin Exp Immunol 85: 413–417.
19. Elies R, Ferrari I, Wallukat G, Lebesgue D, Chiale P, et al. (1996) Structural and
functional analysis of the B cell epitopes recognized by anti-receptor
autoantibodies in patients with Chagas’ disease. J Immunol 157: 4203–4211.
20. Kaplan D, Ferrari I, Bergami PL, Mahler E, Levitus G, et al. (1997) Antibodies
to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess
functional autoreactivity with heart tissue and differ from anti-P autoantibodies
in lupus. Proc Natl Acad Sci U S A 94: 10301–10306.
21. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebesgue D, et al. (1995) Molecular
mimicry between the immunodominant ribosomal protein P0 of Trypanosoma
cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp
Med 182: 59–65.
22. Mahler E, Sepulveda P, Jeannequin O, Liegeard P, Gounon P, et al. (2001) A
monoclonal antibody against the immunodominant epitope of the ribosomal
P2beta protein of Trypanosoma cruzi interacts with the human beta 1-
adrenergic receptor. Eur J Immunol 31: 2210–2216.
23. Mahler E, Hoebeke J, Levin MJ (2004) Structural and functional complexity of
the humoral response against the Trypanosoma cruzi ribosomal P2 beta protein
in patients with chronic Chagas’ heart disease. Clin Exp Immunol 136: 527–534.
24. Sepulveda P, Liegeard P, Wallukat G, Levin MJ, Hontebeyrie M (2000)
Modulation of cardiocyte functional activity by antibodies against trypanosoma
cruzi ribosomal P2 protein C terminus. Infect Immun 68: 5114–5119.
25. Smulski C, Labovsky V, Levy G, Hontebeyrie M, Hoebeke J, et al. (2006)
Structural basis of the cross-reaction between an antibody to the Trypanosoma
cruzi ribosomal P2beta protein and the human beta1 adrenergic receptor.
FASEB J 20: 1396–1406.
26. Levy GV, Tasso LM, Longhi SA, Rivello HG, Kyto V, et al. (2011) Antibodies
against the Trypanosoma cruzi ribosomal P proteins induce apoptosis in HL-1
cardiac cells. Int J Parasitol 41: 635–644.
27. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC,
et al. (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature
454: 486–491.
28. Muller S, Couppez M, Briand JP, Gordon J, Sautiere P, et al. (1985) Antigenic
structure of histone H2B. Biochim Biophys Acta 827: 235–246.
29. Otwinowski Z, Minor W, Charles W. Carter Jr. (1997) [20] Processing of X-ray
diffraction data collected in oscillation mode. Methods in Enzymology:
Academic Press. pp 307–326.
30. Navaza J (1994) AMoRe: an automated package for molecular replacement.
Acta Crystallographica Section A 50: 157–163.
31. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
32. Lopez Bergami P, Scaglione J, Levin MJ (2001) Antibodies against the carboxyl-
terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic.
FASEB J 15: 2602–2612.
33. Stanfield RL, Zemla A, Wilson IA, Rupp B (2006) Antibody elbow angles are
influenced by their light chain class. J Mol Biol 357: 1566–1574.
Crystal Structure of the mAb 17.2-R13 Complex
www.plosntds.org 9 November 2011 | Volume 5 | Issue 11 | e137534. Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, et al. (2003)
Characterization of the human autoimmune response to the major C-terminal
epitope of the ribosomal P proteins. J Mol Med 81: 194–204.
35. Tutor AS, Penela P, Mayor F, Jr. (2007) Anti-beta1-adrenergic receptor
autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells.
Cardiovasc Res 76: 51–60.
36. Soares MR, Bisch PM, Campos de Carvalho AC, Valente AP, Almeida FC
(2004) Correlation between conformation and antibody binding: NMR structure
of cross-reactive peptides from T. cruzi, human and L. braziliensis. FEBS Lett
560: 134–140.
37. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, et al. (2011)
The structural basis for agonist and partial agonist action on a beta(1)-adrenergic
receptor. Nature 469: 241–244.
38. Peter JC, Wallukat G, Tugler J, Maurice D, Roegel JC, et al. (2004) Modulation
of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2
receptor antibody fragments. J Biol Chem 279: 55697–55706.
39. Peter JC, Eftekhari P, Billiald P, Wallukat G, Hoebeke J (2003) scFv single chain
antibody variable fragment as inverse agonist of the beta2-adrenergic receptor.
J Biol Chem 278: 36740–36747.
40. Mijares A, Lebesgue D, Wallukat G, Hoebeke J (2000) From agonist to
antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adreno-
ceptor antibody behave as antagonists. Mol Pharmacol 58: 373–379.
41. Sterin-Borda L, Borda E (2000) Role of neurotransmitter autoantibodies in the
pathogenesis of chagasic peripheral dysautonomia. Ann N Y Acad Sci 917:
273–280.
42. Labovsky V, Smulski CR, Gomez K, Levy G, Levin MJ (2007) Anti-beta1-
adrenergic receptor autoantibodies in patients with chronic Chagas heart
disease. Clin Exp Immunol 148: 440–449.
43. Wallukat G, Munoz Saravia SG, Haberland A, Bartel S, Araujo R, et al. (2010)
Distinct patterns of autoantibodies against G-protein-coupled receptors in
Chagas’ cardiomyopathy and megacolon. Their potential impact for early risk
assessment in asymptomatic Chagas’ patients. J Am Coll Cardiol 55: 463–468.
44. Mao W, Fukuoka S, Iwai C, Liu J, Sharma VK, et al. (2007) Cardiomyocyte
apoptosis in autoimmune cardiomyopathy: mediated via endoplasmic reticulum
stress and exaggerated by norepinephrine. Am J Physiol Heart Circ Physiol 293:
H1636–1645.
45. Jahns R, Schlipp A, Boivin V, Lohse MJ (2010) Targeting receptor antibodies in
immune cardiomyopathy. Semin Thromb Hemost 36: 212–218.
46. Nussinovitch U, Shoenfeld Y (2010) The Clinical Significance of Anti-Beta-1
Adrenergic Receptor Autoantibodies in Cardiac Disease. Clin Rev Allergy
Immunol.
47. Nussinovitch U, Shoenfeld Y (2011) The Diagnostic and Clinical Significance of
Anti-Muscarinic Receptor Autoantibodies. Clin Rev Allergy Immunol.
48. Rosenbaum MB, Chiale PA, Schejtman D, Levin M, Elizari MV (1994)
Antibodies to beta-adrenergic receptors disclosing agonist-like properties in
idiopathic dilated cardiomyopathy and Chagas’ heart disease. J Cardiovasc
Electrophysiol 5: 367–375.
49. Levin MJ, Kaplan D, Ferrari I, Arteman P, Vazquez M, et al. (1993) Humoral
autoimmune response in Chagas’ disease: Trypanosoma cruzi ribosomal
antigens as immunizing agents. FEMS Immunol Med Microbiol 7: 205–210.
50. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein
interfaces. J Mol Biol 234: 946–950.
Crystal Structure of the mAb 17.2-R13 Complex
www.plosntds.org 10 November 2011 | Volume 5 | Issue 11 | e1375